Navigation Links
Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
Date:7/15/2009

CALGARY, July 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation by Dr. Jacqueline Parker et al. entitled "Anti-Tumor Activity of Reovirus is Synergistically Enhanced in Combination with Temozolomide and Low Dose Irradiation in Primary Patient Glioma Xenografts Resistant to Treatment with Either Therapy Alone" was made yesterday at the 28th American Society for Virology (ASV) Annual Meeting. The meeting is being held in Vancouver, British Columbia, from July 11-15, 2009.

"These results support the strategic direction we're taking with the REOLYSIN(R) clinical program," said Dr. Matt Coffey, Chief Operating Officer for Oncolytics. "The future program for REOLYSIN, including our pivotal program, is focused on exploiting these underlying drug synergies."

The poster covers preclinical work using reovirus in combination with low dose irradiation (IR) and temozolomide (TMZ). A panel of glioma cell lines and primary patient glioma explant cells were tested for susceptibility to reovirus, IR, TMZ, or a combination of these therapies in vitro. The combination index analyses revealed moderate to strong synergy in primary patient glioma cells treated with reovirus plus IR and TMZ in vitro. This effect was also seen in vivo in flank tumor xenografts from primary patient tumors resistant to reovirus therapy alone.

The investigators concluded that the data supports the use of reovirus in combination with standard radiation and chemotherapies for the treatment of malignant glioma in humans.

The poster will be available on the Oncolytics website at www.oncolyticsbiotech.com at a later date.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the de
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
4. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
5. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
6. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
7. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
8. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
9. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
10. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) ... the three months ended March 31, 2015 and provided ... in Canadian dollars. Effective July 17, ... May 31 to December 31. As a result of ... for the three months ended March 31, 2015, while ...
(Date:5/5/2015)... VetStem Biopharma, proudly announces former ... Schaffer, DVM, as Director of Veterinary Professional Services. ... experience in the veterinary regenerative medicine field Dr ... veterinarian lead organization”. Dr. Alexis Nahama, President ... be responsible for all technical activities in relationship ...
(Date:5/5/2015)... MILFORD, Mass. , May 5, 2015 ... a strategic alliance which offers a first-of-its-kind platform that ... patient access to lab results, transforms the way patients ... Luminate Health provides a HIPAA-compliant ... patients to access, manage, and understand their lab results, ...
(Date:5/5/2015)... DIEGO , May 5, 2015  Renova™ ... for congestive heart failure and other chronic diseases, ... an independent analysis designed to reflect the healthcare ... time. This model will be used to characterize ... CHF, could have on those groups of patients ...
Breaking Biology Technology:Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3
... 3, 2011  Generex Biotechnology Corporation ( www.generex.com ) (OTCBB: ... to the early diagnosis, and possibly treatment of, Type ... Class II Epitope Hybrids Derived from Proinsulin and GAD ... appears in the April issue of the international peer-reviewed ...
... SAN DIEGO, May 3, 2011 Verenium Corporation (NASDAQ: ... and commercialization of high-performance industrial enzyme solutions, today announced ... 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing. ... the Toronto Convention Center.   James Levine, ...
... VIEW, Calif., May 3, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: ... first quarter ended March 31, 2011. The net ... $17.6 million compared to a net loss of $14.1 million ... first quarter ended March 31, 2011 was related primarily to ...
Cached Biology Technology:Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes 2Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes 3Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes 4Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing 2Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... This release is available in German . ... channels and ion pumps, and thus specifically control them with ... J. Zlch Prize 2012 to four scientists who initiated and ... optogenetics: Ernst Bamberg of the Max Planck Institute of Biophysics ...
... lot of all the hens in the flock, but the ... sperm - and thus more chicks. This sounds natural, but ... of years, people have tinkered with the development of domestic ... large muscle mass and increased egg-laying, we have at the ...
... autism researchers in the University of North Carolina School of ... latest round of funding from the National Institutes of Health,s ... was ranked No. 2 among the top 25 institutions in ... Autism Coordinating Committee, is one of only two institutions that ...
Cached Biology News:Zülch Prize 2012 for founders of optogenetics 2Zülch Prize 2012 for founders of optogenetics 3Zülch Prize 2012 for founders of optogenetics 4For the rooster, size matters 22 UNC faculty receive Autism Centers of Excellence grants for new research 22 UNC faculty receive Autism Centers of Excellence grants for new research 3
... The pYD1 Yeast Display Vector is specifically ... on the surface of Saccharomyces cerevisiae. Displayed ... to interact with known or putative ligands. ... which consists of two domains Aga1 and ...
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
... Polyclonal Antibody against Aph-1a (Aph-1aL,S ... The gamma secretase is a multiprotein ... and Pen-2; all four proteins are ... gamma secretase complex catalyzes cleavage of ...
... Bio-Beads S-X media are ... for size exclusion chromatography of ... that require organic eluents. The ... toluene, xylene, carbon tetrachloride, dimethylformamide, ...
Biology Products: